Interleukin 2 in cancer therapy.
Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.
Antony
G K
GK
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
Dudek
A Z
AZ
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008545:Melanoma / Q000188:drug therapy*; D015375:Receptors, Interleukin-2 / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
D000970:Antineoplastic Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2